you, Thank financial our third today and you, quarter operating Maria, us thank joining everyone, XXXX and for to discuss results.
year third quarter in quarter. to company The same profit year-over-year third the quarter $X.XX increase the of for for as margins were second totaled all across the key XX.X% XXX% last XX.X% compared record was our metrics. and yet previous for of Gross of for period quarter the XXXX million, quarter sequentially. financial and Revenue the XX.X% another XXX% an
cash Adjusted in sequentially, of also QX contract from which 'XX $XXX,XXX revenue loss XX% QX narrowed a to a Becoming EBITDA, year-over-year contributing sequentially. is positive $XXX,XXX increased and approximately priority has of XXX% in flow last been Branded while manufacturing non-GAAP a measure, XXXX. the ours. margin expansion financial to consumer revenue sequentially, increased quarter
which we the to QX, With achieving are we growth very goal. we into continue to in expect growth QX, close experienced this
the beauty eyeliner, Branded the contribution a and company In Products, full focused and brand, from quarter quarter eyelashes, revenue cosmetics Silly Mascara. our first lash growth George on third of bake serum Consumer was
As the a $X we reminder, run in rate on acquired approximately revenue May, X brand George when million. ago months a Silly of was
marketing, rate holidays. Since have then, new now the of we Amazon the products is we them on which heading our into and introduce run million launched $X on that are optimized result a
continue also the brands. and demand. completion in QX year-over-year both from of the order new we in see increases manufacturing, and relationships expansion client to the Kenkoderm support growth facility resulting have We our to our [ In of ] the Texas saw MetaGel contract
from We state-of-the-art manufacturing doubled second in footage facility impacted the related $XXX,XXX and approximately QX, an in to during machinery expansion in increase Due clean by automated it Contract operations. our prior increasing quarter, and shutting QX and the was QX restarting $XXX,XXX down square facilities. the of validate move in equipment to normalized XXX%. our of room invested to revenue to
food million ] oxidase can diamine conditions. in and treat revenues sold with announced [ which gut our issues selling Europe's HistaSolve, is recently Daosin We cause migraines of generating first relationship This to as Our Europe. product, which release $XX enzyme progress intolerance, in supplement, continues the skin ] STADA [ ] and histamine #X to is well well. headaches, annualized [ over
customers ] businesses over first distribute will aid X Silverseal. and service. and [ its flagship a provider to sectors our to public in In agreement identity such QX, we and Corporation, North announced product, products as services to manufacturing, America with [ hospitality many of across corporate million Cintas Cintas leading supply ] a distribute safety Silverseal uniforms,
the dressing, of Cintas' [ hydrogel burns, hospital-grade are ] customers audience employees for a for the target this ideal As wounds, product.
for This partnership for Silver brand is Seal's significant revenue also the but awareness. us, not to only associated
are contribute The the delivered of quarter of current Seal expected first during XXXX, growth our which to being fourth Silver orders quarter-over-quarter. revenue will
the global guidelines products medical, surgical conducted personal safety and protective Optics have In review and we with addition equipment an contract aesthetic [indiscernible] our or funded applications. leading FDA businesses, manufacturing products to and branded and goal institutional device In aspirational health facilities. by in study accordance in IRB innovative board July, supplier we on shots several medical U.S. of announced a launch for of care
hair has and effective Laser to proven removal hair. be permanently removing
with associated Ploom which particles release long-term a the compounds, of affect professionals the and be providing is may inhaled hazardous that can it airborne organic and of treatments. ] [ However, short-term the contains health
of the So hydrogel potentially much presently, Ploom offer long-needed hazards solution ] for a [ skin [ and exposure removal to to content [ hair water the high use may the of systems of dozen ] order when states mandating that the enacted the risks Our so before mitigate ] a the well Ploom. surface over to begins. laser applied of legislation in absorbing ploom and capturing industry-wide during evacuation procedure
experienced human more the pain hair solution Research amount be a could In the Center effective the the conducted the application hydrogel initiated of surgeons. plastic regulatory for by we Together at requirements and trial also addition, meets removal, the of being laser Clinical that may during have with treatment Vanilla, for practical compliance. for future Florida a allow reduce
will primary during air being hydrogen laser of the to reduction treatments applied Our in Ploom procedures. XX the measure these patients to prior the be hair removal outcome with
are we laser study quarter technology. hair potential hydrogel the into top many untapped our data for data, the market. commercially during unique fourth the applications of from large removal receiving expect launch XXXX. Upon successful We line There can
solutions a Ocular as eye leader instruments at the of technology serves Board in advanced America as on Kip sitting Cracker innovative Directors surgical on Advisory focused decades He our VP North company a sales of biotech appointed the and who well experience. Board, development over as X Microsurgical Science, device of recently Scientific management brings We care and to of medical cost-effective products. Sales and currently
Prior current served Surgical, positions his role, Medical Stryker STAR Abbott and various to [indiscernible] Optics, in at more. sales including companies Endoscopy leadership Mr.
cash will opportunities our core not appropriately vision and so these division With to lead unlock to contract to branded strategically manufacturing resources not significantly, and to commercial confident or perform well will of applications our we and each the large continue company's and product hydrogel. pads other and we R&D grow that While certainly said, for feel be our exploration managing pursuing done of that being that our overextending high ROI be thoughtfully will future.
Looking ahead expect all across lines. into continued QX, we growth revenue of our
and million revenue exceed approach expect to We $X positive to operating in continue QX. to cash improve flow and
As revenue does revenues rapid start exclusive their to of pads appearance. supplier their of still XXXX, guidance device the and the continue on expect we our gel reduced any team for a incorporate revenue from sonic acoustic not as in reminder, QX AbbVie our for with cellulite with those for launch. to QX work Pulse still partnership We closely
Board at lockup subject members for a of we approximately the team of in from Lastly, X-month are and gross the Directors million to Insiders $X earlier of this offering. terms. including participated the attractive of a proceeds closing. period financing Insiders, completed management week, date
growth marketing customers. capital and and Drapczuk. like increase our from our the spend with over to for us provide buy will CFO, financing the that, I our to inventory our brands Adam? support to the would receivables turn With of working This large Adam call
